New vaccine combo aims to halt prostate cancer growth without surgery

NCT ID NCT07574541

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 36 times

Summary

This phase 2 trial tests a combination of a vaccine (TriAdeno) and an immune-boosting drug (N-803) in 52 men with early-stage, low- or medium-risk prostate cancer who are currently on active surveillance. The vaccine targets three proteins found in prostate cancer cells, while N-803 helps activate the immune system. The goal is to see if this treatment can increase immune cell activity inside the tumor and potentially slow or stop cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TriAdeno vaccine and N-803 (a drug that boosts the immune system)
What this could lead to
If it works, this could help men with early-stage prostate cancer avoid or delay more aggressive treatments like surgery or radiation.
What could go wrong
This is a small, early-phase trial (52 people) testing safety and immune response, not yet proven to stop cancer growth. Side effects from the vaccine and N-803 are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.